9 completed, 9 recruiting, 6 active not recruiting, 4 terminated. 19 Phase 2, 11 Phase 1, 1 Not applicable, 1 Phase 3.
Follow Hairy Cell Leukemia: new trials by email Literature Review of Hairy Cell Leukemia trials Research Report on Hairy Cell Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies LMY-922 - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Not yet recruiting | Luminary Therapeutics | 27 | 2026-09-01 | 2026-07-01 |
| Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant Zanubrutinib - Hairy Cell Leukemia, Hairy Cell Leukemia Variant | Phase 2 | Enrolling by invitation | Bnai Zion Medical Center | 12 | 2026-06-01 | 2026-07-08 |
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 84 | 2026-05-29 | 2026-07-31 |
| Assessment of Disease Burden in Hairy Cell Leukemia Peripheral and BM blood sample - Hairy Cell Leukemia | Not applicable | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 45 | 2025-01-01 | 2025-01-17 |
| A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL) Vemurafenib, Obinutuzumab, Cladribine - Hairy Cell Leukemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 86 | 2024-09-09 | 2026-09-09 |
| Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients Hairy Cell Leukemia | Unknown | Power Life Sciences Inc. | 500 | 2024-06-01 | 2023-05-16 | |
| AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas CD22CART Infusion - Follicular Lymphoma, Mantle Cell Lymphoma | Phase 1 | Recruiting | Stanford University | 148 | 2024-03-29 | 2026-08-12 |
| Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant CD22CART cell infusion - Hairy Cell Leukemia, Hairy Cell Leukemia Variant | Phase 1 | Recruiting | National Cancer Institute (NCI) | 27 | 2022-05-23 | 2026-10-16 |
| Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia Low dose vemurafenib plus rituximab - Hairy Cell Leukemia | Phase 2 | Completed | Scripps Health | 15 | 2022-03-02 | 2026-04-24 |
| Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. Prior MB-102 CAR-T cell investigational product., Prior MB-106 CAR-T cell investigational product. - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse | Terminated | Mustang Bio | 3 | 2021-09-29 | 2024-07-22 | |
| Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. LP-168 - CLL/SLL, Waldenstrom Macroglobulinemia | Phase 1 | Recruiting | Newave Pharmaceutical Inc | 60 | 2021-07-19 | 2026-02-13 |
| B-cell Chronic Lymphoid Malignancies Markers Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma | Unknown | University Hospital, Strasbourg, France | 420 | 2021-06-14 | 2021-07-07 | |
| Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant binimetinib - Hairy Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 40 | 2021-01-07 | 2026-10-16 |
| Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL binimetinib, Encorafenib - Hairy Cell Leukemia | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 28 | 2020-10-28 | 2026-06-12 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Anti-CD123/CD3 Monoclonal Antibody MGD006 - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Withdrawn | City of Hope Medical Center | 2020-10-20 | 2020-12-17 | |
| US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI) Hairy Cell Leukemia | Terminated | AstraZeneca | 2 | 2019-12-09 | 2025-07-18 | |
| Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia Moxetumomab Pasudotox-tdfk, Rituximab, Ruxience - Hairy Cell Leukemia | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 18 | 2019-10-03 | 2026-06-29 |
| A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia Vemurafenib, Obinutuzumab - Hairy Cell Leukemia, Leukemia | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2018-02-09 | 2026-08-24 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab - Anemia, B-Cell Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Alexey Danilov, MD | 24 | 2017-07-17 | 2023-08-08 |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Acalabrutinib, Pembrolizumab - Follicular Lymphoma (FL), CLL | Phase 1 / Phase 2 | Completed | Acerta Pharma BV | 161 | 2015-02-20 | 2026-05-13 |
Showing 20 of 34. Sign in to see all of them.
Leukemia, Hairy Cell (34) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Leukemia (5) · Lymphoma, Follicular (5) · Lymphoma, Mantle-Cell (5) · Lymphoma, B-Cell, Marginal Zone (4) · Waldenstrom Macroglobulinemia (4) · Recurrence (3) · Blastic Plasmacytoid Dendritic Cell Neoplasm (2) · Burkitt Lymphoma (2) · Hematologic Neoplasms (2) · Hodgkin Disease (2) · Leukemia, Biphenotypic, Acute (2) · Lymphoma (2) · Lymphoma, Large B-Cell, Diffuse (2)
Hematologic Diseases (34) · Hemic and Lymphatic Diseases (34) · Immune System Diseases (34) · Immunoproliferative Disorders (34) · Lymphatic Diseases (34) · Lymphoproliferative Disorders (34) · Neoplasms (34) · Neoplasms by Histologic Type (34) · Leukemia (29) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Disease Attributes (9) · Chronic Disease (7) · Leukemia, Lymphoid (7) · Cardiovascular Diseases (6)
Rituximab (7) · Cladribine (4) · Vemurafenib (4) · immunotoxin HA22 (3) · obinutuzumab (3) · Acetaminophen (2) · Biopsy (2) · CT-P10 (2) · Diphenhydramine (2) · Specimen Handling (2) · binimetinib (2) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · Adrenal Cortex Hormones (1) · Aspirin (1) · B3(Fv)-PE38KDEL recombinant immunotoxin (1)
National Cancer Institute (NCI) (11) · Memorial Sloan Kettering Cancer Center (3) · Acerta Pharma BV (1) · Alexey Danilov, MD (1) · AstraZeneca (1) · Bnai Zion Medical Center (1) · Cambridge Antibody Technology (1) · Children's Oncology Group (1) · City of Hope Medical Center (1) · Fore Biotherapeutics (1) · HaEmek Medical Center, Israel (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Luminary Therapeutics (1) · M.D. Anderson Cancer Center (1) · MedImmune LLC (1)
United States (27) · Poland (2) · Australia (1) · Canada (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · New Zealand (1) · Puerto Rico (1) · Switzerland (1) · United Kingdom (1)
Robert J Kreitman, M.D. (8) · Jae Park, MD (2) · Alan Saven, MD (1) · Archna Hale (1) · Bruce Dezube, M.D. (1) · Craig Okada, M.D. (1) · Farhad Ravandi-Kashani (1) · Ibrahim Aldoss, MD (1) · Jae H. Park, MD (1) · Juan Cuevas (1) · Kerry A Rogers (1) · Mathias J Rummel, Prof. Dr. (1) · Matthew Frank, MD, PhD (1)
PMID 18596230, PMID 41980020, PMID 21821712, PMID 22355053, PMID 26352686, PMID 29487070, PMID 32109194, PMID 33754642, PMID 34196037, PMID 34607348, PMID 35930750, PMID 38320179, PMID 41060318, PMID 41236721, PMID 42308249
UM1CA186712 (2), N01CM00039 (1), P30CA016058 (1), U01CA076576 (1), U10CA098543 (1), UG1CA189958 (1)